Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, August 2003, p. 2636-2639, Vol. 47, No. 8
0066-4804/03/$08.00+0 DOI: 10.1128/AAC.47.8.2636-2639.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
INSERM U511, Immuno-biologie Cellulaire et Moléculaire des Infections Parasitaires, CHU Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Université Pierre et Marie Curie-Paris, 75013 Paris,1 Laboratoire de Parasitologie-Mycologie and Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, 75010 Paris, France,2 Department of Medical Microbiology, University of Nijmengen, Nijmengen, The Netherlands3
Received 2 December 2002/ Returned for modification 10 March 2003/ Accepted 7 May 2003
The in vitro activities of 25 quinolones and fluoroquinolones against erythrocytic stages of Plasmodium falciparum and against liver stages of Plasmodium yoelii yoelii and P. falciparum were studied. All compounds were inhibitory for chloroquine-sensitive and chloroquine-resistant P. falciparum grown in red blood cells. This inhibitory effect increased with prolonged incubation and according to the logarithm of the drug concentration. Grepafloxacin, trovafloxacin, and ciprofloxacin were the most effective drugs, with 50% inhibitory concentrations of <10 µg/ml against both strains. Only grepafloxacin, piromidic acid, and trovafloxacin had an inhibitory effect against hepatic stages of P. falciparum and P. yoelii yoelii; this effect combined reductions of the numbers and the sizes of schizonts in treated cultures. Thus, quinolones have a potential for treatment or prevention of malaria through their unique antiparasitic effect against erythrocytic and hepatic stages of Plasmodium.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»